...

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

【24h】

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

机译：Daratumumab，来那度胺和地塞米松与来那度胺和地塞米松在复发或难治性多发性骨髓瘤患者中有1至3疗程的疗效：最新的Pollux分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共7页
作者
Usmani Saad Z.; Dimopoulos Meletios A.; Belch Andrew; White Darrell; Benboubker Lofti; Cook Gordon; Leiba Merav; Morton James; Ho P. Joy; Kim Kihyun; Takezako Naoki; Khokhar Nushmia Z.; Guckert Mary; Wu Kaida; Qin Xiang; Casneuf Tineke; Chiu Christopher; Sasser A. Kate; San-Miguel Jesus;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux [J] . Moreau Philippe, Kaufman Jonathan L., Sutherland Heather J., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：达那他单抗，来那度胺和地塞米松与来那度胺和地塞米松单独对先前治疗暴露量为1-3的复发或难治性多发性骨髓瘤患者的疗效：基于以前的治疗暴露：Pollux的最新分析
2. Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux [J] . Usmani Saad Z., Dimopoulos Meletios A., Belch Andrew, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：Daratumumab，来那度胺和地塞米松与来那度胺和地塞米松在复发或难治性多发性骨髓瘤患者中有1至3疗程的疗效：最新的Pollux分析
3. Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux [J] . Usmani Saad Z., Dimopoulos Meletios A., Belch Andrew, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：Daratumumab，来那度胺和地塞米松与来那度胺和地塞米松在复发或难治性多发性骨髓瘤患者中有1至3疗程的疗效：最新的Pollux分析
4. THALIDOMIDE PLUS INTERMEDIATE-DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED AL PATIENTS [C] . Giovanni Palladini, Vittorio PerfettF, Stefano Perlini, International Symposium on Amyloidosis . 2005

机译：沙利度胺加上难治性/复发患者中的中间剂量地塞米松
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX [O] . Meletios A. Dimopoulos, Jesus San-Miguel, Andrew Belch, 2018

机译：Daratumumab加来那度胺和地塞米松与来那度胺和地塞米松在复发或难治性多发性骨髓瘤中的最新研究：POLLUX的最新分析
7. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX [O] . Meletios A. Dimopoulos, Jesus San-Miguel, Andrew Belch, 2018

机译：Daratumumab Plus Lenalalomide和地塞米松与Lenalal omide和地塞米松复发或难治性多发性多发性骨髓瘤：对Pollux的更新分析

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号